Table 1b.
Allogeneic-specific baseline characteristics
| High (>75%) N=15 |
Medium (50-75%) N=18 |
Low (<50%) N=30 |
None (0%) N=55 |
P-value1 | |
|---|---|---|---|---|---|
| Stem Cell Source | 0.12 | ||||
| Peripheral Blood | 9 (60%) | 15 (83.3%) | 24 (80%) | 36 (65.5%) | · |
| Bone Marrow | 4 (26.7%) | 0 (0%) | 5 (16.7%) | 7 (12.7%) | · |
| Umbilical Cord Blood | 2 (13.3%) | 3 (16.7%) | 1 (3.3%) | 12 (21.8%) | · |
| HLA Matching/ Donor Type | 0.25 | ||||
| MRD2 | 5 (33.3%) | 6 (33.3%) | 16 (53.3%) | 14 (25.5%) | · |
| MUD3 | 8 (53.3%) | 8 (44.4%) | 10 (33.3%) | 24 (43.6%) | · |
| MMRD4 | 0 (0%) | 1 (5.6%) | 3 (10%) | 5 (9.1%) | · |
| Mismatched UCB5 | 2 (13.3%) | 3 (16.7%) | 1 (3.3%) | 12 (21.8%) | · |
| Myeloablative Conditioning | 14 (93.3%) | 17 (94.4%) | 28 (93.3%) | 53 (96.4%) | 0.92 |
| T-Cell Serotherapy6 | 3 (20%) | 3 (16.7%) | 15 (50%) | 18 (32.7%) | 0.07 |
| GVHD7 Prophylaxis | 0.72 | ||||
| CNI/MMF8 | 4 (26.7%) | 3 (16.7%) | 2 (6.7%) | 12 (21.8%) | · |
| CNI/MTX9 | 10 (66.7%) | 14 (77.8%) | 23 (76.7%) | 36 (65.5%) | · |
| PTCy10 | 1 (6.7%) | 1 (5.6%) | 3 (10%) | 5 (9.1%) | · |
| Other | 0 (0%) | 0 (0%) | 2 (6.7%) | 2 (3.6%) | · |
1
P-values obtained via chi-square test.
2
MUD: Matched Unrelated Donor.
3
MRD: Matched Related Donor.
4
MMRD: Mismatched Related Donor.
5
UCB: Umbilical Cord Blood.
6
T-Cell Serotherapy: Alemtuzumab or Anti-Thymocyte Globulin.
7
GVHD: Graft-Versus-Host Disease.
8
CNI/MMF: Calcineurin Inhibitor/ Mycophenolate mofetil.
9
CNI/MTX: Calcineurin Inhibitor/ Methotrexate.
10
PTCy: Post-transplant Cyclophosphamide.